New CEO Mattessich Brings in New Skills, Leadership to Help Ocular Therapeutix Reach Potential
New CEO Antony Mattessich says Ocular Therapeutix has learned its mistakes after receiving two CRLs from the FDA. With new leadership and a clear vision, the company is ready to push forward as a full-fledged biopharmaceutical company.
Activity